Investor Pfizer Inc
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Pfizer Inc . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-03-24 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 661,709,764 0
2025-03-20 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 661,709,764 661,709,764
2025-02-27 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 661,709,764 661,709,764
2025-02-12 13G/A ZURA / Zura Bio Limited 2,970,022 2,970,022
2025-02-12 13G/A CRDF / Cardiff Oncology, Inc. 2,411,575 2,411,575
2025-01-21 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 661,709,764
2025-01-16 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 1,361,709,764 1,361,709,764
2024-10-03 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,062,236,079 1,361,709,764
2024-10-01 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,062,236,079 2,062,236,079
2024-08-05 13D/A CERE / Cerevel Therapeutics Holdings, Inc. 27,349,211 0
2024-07-29 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,062,236,079 2,062,236,079
2024-03-22 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,955,063,626 2,062,236,079
2024-03-19 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,955,063,626 2,955,063,626
2024-03-15 13G/A TRML / Tourmaline Bio, Inc.
2024-02-14 13G/A EFTR / eFFECTOR Therapeutics, Inc. 2,243,850 2,243,850
2024-02-14 13G/A ELVN / Enliven Therapeutics, Inc. 389,429
2024-02-14 13G/A / AN2 THERAPEUTICS 1,362,499 1,362,499
2024-02-14 13G/A CLLS / Cellectis S.A. - Depositary Receipt (Common Stock) 2,786,924 2,786,924
2024-02-14 13G/A AKRO / Akero Therapeutics, Inc. 2,525,252 2,525,252
2024-01-29 13D/A LBPH / Longboard Pharmaceuticals, Inc. 3,978,540 0
2024-01-19 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,955,063,626
2024-01-10 13D/A LBPH / Longboard Pharmaceuticals, Inc. 3,978,540 3,978,540
2023-10-27 13G TRML / Tourmaline Bio, Inc.
2023-10-25 13D/A ALLO / Allogene Therapeutics, Inc. 22,032,040 22,032,040
2023-10-18 13D/A CERE / Cerevel Therapeutics Holdings, Inc. 27,349,211 27,349,211
2023-10-10 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,955,063,626
2023-09-11 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,955,063,626
2023-07-10 13G CRBU / Caribou Biosciences, Inc.
2023-05-15 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,955,063,626
2023-03-30 13G ZURA / Zura Bio Limited 2,970,022
2023-03-27 13D/A LBPH / Longboard Pharmaceuticals, Inc. 3,978,540 3,978,540
2023-03-23 13G/A PYXS / Pyxis Oncology, Inc. 5,221,176 7,032,770
2023-02-13 13G/A PYXS / Pyxis Oncology, Inc. 2,991,522 5,221,176
2023-02-13 13G ANTX / AN2 Therapeutics, Inc. 1,362,499
2023-02-01 13D/A HLN / Haleon plc - Depositary Receipt (Common Stock) 2,955,063,626
2022-12-29 13G ORIC / ORIC Pharmaceuticals, Inc.
2022-07-27 13D HLN / Haleon plc - Depositary Receipt (Common Stock) 2,955,063,626
2022-06-29 13G VALN / Valneva SE
2022-06-28 13G AKRO / Akero Therapeutics, Inc. 2,525,252
2022-04-07 13D/A CERE / Cerevel Therapeutics Holdings, Inc. 27,349,211 27,349,211
2022-04-07 13D/A ALLO / Allogene Therapeutics, Inc. 22,032,040 22,032,040
2022-03-21 13D LBPH / Longboard Pharmaceuticals, Inc. 3,978,540
2022-02-14 13G EFTR / eFFECTOR Therapeutics, Inc. 2,243,850
2022-02-14 13G/A SWTX / SpringWorks Therapeutics, Inc. 4,583,047 2,340,330
2022-02-14 13G/A CFRX / ContraFect Corp 1,785,267 1,785,267
2022-02-14 13G/A CRTX / Cortexyme Inc 2,056,377 600,000
2022-02-11 13G/A EPIX / ESSA Pharma Inc. 1,675,000 1,675,000
2022-02-11 13G/A BCAB / BioAtla, Inc. 2,238,090 1,372,052
2022-02-11 13G PYXS / Pyxis Oncology, Inc. 2,991,522
2022-02-11 13G/A WVE / Wave Life Sciences Ltd. 1,875,000 1,875,000
2022-02-11 13G/A FDMT / 4D Molecular Therapeutics, Inc. 1,666,658 341,658
2021-11-19 13G CRDF / Cardiff Oncology, Inc. 2,411,575
2021-09-20 13G ARVN / Arvinas, Inc. 3,457,815
2021-09-17 13D/A CERE / Cerevel Therapeutics Holdings, Inc. 27,349,211 27,349,211
2021-09-17 13D/A ALLO / Allogene Therapeutics, Inc. 22,032,040 22,032,040
2021-07-09 13G SPRO / Spero Therapeutics, Inc. 2,362,348
2021-07-09 13D/A CERE / Cerevel Therapeutics Holdings, Inc. 27,349,211 27,349,211
2021-03-25 13G/A CRTX / Cortexyme Inc 2,143,372 2,056,377
2021-02-16 13G/A CRTX / Cortexyme Inc 2,143,372 2,143,372
2021-02-16 13G FDMT / 4D Molecular Therapeutics, Inc. 1,666,658 1,666,658
2021-02-16 13G BCAB / BioAtla, Inc. 2,238,090 2,238,090
2021-02-16 13G/A CRTX / Cortexyme Inc 2,143,372 2,143,372
2021-02-16 13G BCAB / BioAtla, Inc. 2,238,090 2,238,090
2021-02-16 13G FDMT / 4D Molecular Therapeutics, Inc. 1,666,658
2021-02-12 13G/A CFRX / ContraFect Corp 11,111,111 1,785,267
2021-02-12 13G/A SWTX / SpringWorks Therapeutics, Inc. 4,593,847 4,583,047
2021-02-12 13G/A MORF / Morphic Holding, Inc. 2,528,835 1,265,635
2021-02-12 13G/A MRSN / Mersana Therapeutics, Inc. 2,209,631 0
2020-11-19 13G FIXX / Homology Medicines, Inc. 5,000,000
2020-11-06 13D CERE / Cerevel Therapeutics Holdings, Inc. 27,349,211
2020-08-06 13G EPIX / ESSA Pharma Inc. 1,675,000
2020-03-26 13G IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF 1,557,722
2020-02-14 13G SWTX / SpringWorks Therapeutics, Inc. 4,593,847
2020-02-14 13G MORF / Morphic Holding, Inc. 2,528,835
2019-12-16 13G CFRX / ContraFect Corp 11,111,111
2019-05-22 13G NXTC / NextCure, Inc. 1,970,759
2019-02-13 13G/A GEMP / Gemphire Therapeutics Inc. 675,250 675,250
2019-02-13 13G/A RYTM / Rhythm Pharmaceuticals, Inc. 1,427,639
2018-11-16 13D/A ICUI / ICU Medical, Inc. 25,000,001 0
2018-10-22 13D ALLO / Allogene Therapeutics, Inc. 22,032,040
2018-08-15 13D/A ICUI / ICU Medical, Inc. 3,200,000 2,500,000
2018-02-13 13G/A PLX / Protalix BioTherapeutics, Inc. 5,649,079 5,649,079
2018-02-13 13G/A SYBX / Synlogic, Inc. 356,797
2018-02-13 13G/A CTMX / CytomX Therapeutics, Inc. 2,017,604 0
2018-02-13 13G/A MRSN / Mersana Therapeutics, Inc. 2,209,631
2018-02-13 13G/A MRUS / Merus N.V. 1,142,548 260,942
2017-10-18 13G RYTM / Rhythm Pharmaceuticals, Inc. 1,427,639
2017-07-13 13G MRSN / Mersana Therapeutics, Inc. 2,232,221
2017-05-26 13D/A PSDV / pSivida Corp. 1,862,093 1,862,093
2017-02-13 13G GEMP / Gemphire Therapeutics Inc. 675,250
2017-02-13 13D ICUI / ICU Medical, Inc. 3,200,000
2016-06-06 13G MRUS / Merus N.V. 1,142,548
2016-05-12 13G WVE / Wave Life Sciences Ltd. 1,875,000
2016-04-04 13G/A EIGR / Eiger BioPharmaceuticals, Inc. 1,828,495 121,899
2016-03-17 13D/A ARQL / ArQule, Inc. 3,273,679 3,273,679
2016-02-16 13G CLLS / Cellectis S.A. - Depositary Receipt (Common Stock) 2,786,924
2016-02-11 13G/A SYBX / Synlogic, Inc. 2,489,364 2,497,586
2016-02-11 13G/A FLXN / Horizon Funds - Horizon Flexible Income ETF 926,309
2016-02-11 13G/A EIGR / Eiger BioPharmaceuticals, Inc. 1,828,495
2016-02-11 13G/A US33830X1046 / Five Prime Therapeutics Inc 0
2015-10-23 13G PLX / Protalix BioTherapeutics, Inc. 5,649,079
2015-10-21 13G CTMX / CytomX Therapeutics, Inc. 2,017,604
2015-10-14 13G SYBX / Synlogic, Inc. 2,489,364
2015-08-18 13G/A NLTX / Neoleukin Therapeutics, Inc. 481,529
2015-05-01 13D/A ARQL / ArQule, Inc. 3,273,679
2015-05-01 13D/A PSDV / pSivida Corp. 1,862,093
2015-02-05 13G FLXN / Horizon Funds - Horizon Flexible Income ETF 1,687,250
2015-02-05 13G/A ESPR / Esperion Therapeutics, Inc. 966,218
2014-03-21 13G NLTX / Neoleukin Therapeutics, Inc. 1,235,330
2014-02-14 13G EIGR / Eiger BioPharmaceuticals, Inc. 1,794,803
2014-02-13 13G ESPR / Esperion Therapeutics, Inc. 966,218
2014-02-13 13G TLOG / TetraLogic Pharmaceuticals Corporation 1,548,241
2013-09-27 13G US33830X1046 / Five Prime Therapeutics Inc 1,576,585
2013-02-14 13G/A CLVS / Clovis Oncology Inc 1,181,190
2012-03-09 13G CLVS / Clovis Oncology Inc 1,181,190